425: TuHURA Biosciences Announces Abstracts Accepted for Poster Presentation at 2025 AACR Annual Meeting

TuHURA Biosciences announces that abstracts highlighting Kineta Inc.'s KVA12123 antibody and Moffitt Cancer Center scientists' examination of IFx-Hu2.0 therapy mechanisms have been selected for poster presentation at the AACR Annual Meeting 2025.

Summary

• TuHURA Biosciences announced that abstracts related to Kineta's KVA12123 antibody and TuHURA's IFx-Hu2.0 therapy have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025.
• The AACR Annual Meeting will take place from April 25-30, 2025, in Chicago, IL.
• One abstract highlights initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors.
• Another abstract examines mechanistic insights into IFx-Hu2.0 responses in the first human trial after prior anti-PD-1 therapy failure.
• TuHURA is in the process of acquiring Kineta, including the rights to the KVA12123 antibody, in a merger transaction expected to close in Q2 2025.
• TuHURA is preparing to initiate a Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first line treatment for advanced or metastatic Merkel Cell Carcinoma.

Sentiment

Score: 7

Explanation: The announcement is positive, highlighting research progress and strategic acquisitions. However, it also includes cautionary language regarding forward-looking statements and potential risks.

Positives

• Acceptance of abstracts at the AACR Annual Meeting provides visibility for TuHURA's and Kineta's research.
• The planned Phase 3 trial for IFx-2.0 represents a significant step in its development.
• The acquisition of Kineta expands TuHURA's pipeline with the addition of KVA12123.

Risks

• The merger with Kineta is subject to funding and other closing conditions, which may not be satisfied.
• The Phase 3 trial for IFx-2.0 may not be successful.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

TuHURA anticipates closing the merger with Kineta in Q2 2025 and initiating a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to Keytruda for Merkel Cell Carcinoma.

Industry Context

The announcement highlights TuHURA's focus on overcoming resistance to cancer immunotherapy, a significant challenge in the field. The company is leveraging both innate immune agonists and antibody-drug conjugates to address this issue. The collaboration with Moffitt Cancer Center and the acquisition of Kineta demonstrate a multi-faceted approach to drug development.

Comparison to Industry Standards

• TuHURA's approach of combining IFx-2.0 with pembrolizumab (Keytruda) mirrors strategies employed by companies like Merck, which developed Keytruda, and others exploring combination therapies to enhance checkpoint inhibitor efficacy.
• The development of bi-specific antibody drug conjugates targeting Myeloid Derived Suppressor Cells aligns with efforts by companies like Roche and Amgen, which are also developing novel immunotherapies to modulate the tumor microenvironment.
• Kineta's KVA12123 antibody, targeting VISTA, is similar to programs from companies like Jounce Therapeutics and Compass Therapeutics, which are also exploring VISTA as an immune checkpoint target.

Stakeholder Impact

• Positive for shareholders due to potential pipeline expansion and research advancements.
• Positive for patients with advanced solid tumors and Merkel Cell Carcinoma, as new treatment options are being explored.
• Positive for employees of both TuHURA and Kineta, as the merger could create new opportunities.

Next Steps

• TuHURA will present the abstracts at the AACR Annual Meeting in April 2025.
• TuHURA will work to satisfy the closing conditions for the merger with Kineta, targeted for Q2 2025.
• TuHURA will prepare to initiate a Phase 3 registration trial of IFx-2.0.

Key Dates

Keywords

TuHURA Biosciences, Kineta, KVA12123, IFx-Hu2.0, AACR Annual Meeting, Immuno-oncology, Phase 3 trial, Merger, Antibody, Pembrolizumab, Keytruda, Merkel Cell Carcinoma